Otis W. Brawley Purchases 35,640 Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) Stock

Lyell Immunopharma, Inc. (NASDAQ:LYEL - Get Free Report) Director Otis W. Brawley acquired 35,640 shares of the firm's stock in a transaction that occurred on Monday, March 31st. The stock was bought at an average price of $0.56 per share, with a total value of $19,958.40. Following the completion of the acquisition, the director now directly owns 35,640 shares of the company's stock, valued at $19,958.40. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Lyell Immunopharma Price Performance

Shares of LYEL traded down $0.02 during trading hours on Monday, hitting $0.45. 764,272 shares of the stock were exchanged, compared to its average volume of 1,062,058. The firm has a market capitalization of $131.85 million, a P/E ratio of -0.57 and a beta of -0.26. Lyell Immunopharma, Inc. has a fifty-two week low of $0.41 and a fifty-two week high of $3.15. The business has a 50-day moving average of $0.60 and a 200-day moving average of $0.83.

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last issued its quarterly earnings results on Wednesday, March 12th. The company reported ($0.72) earnings per share for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.52). Lyell Immunopharma had a negative return on equity of 34.64% and a negative net margin of 323,792.09%. The business had revenue of $0.01 million for the quarter. As a group, analysts forecast that Lyell Immunopharma, Inc. will post -0.78 earnings per share for the current fiscal year.

Institutional Trading of Lyell Immunopharma

Large investors have recently modified their holdings of the stock. Public Employees Retirement System of Ohio bought a new position in Lyell Immunopharma during the fourth quarter worth $64,000. venBio Partners LLC bought a new stake in Lyell Immunopharma in the 4th quarter valued at about $4,545,000. Two Sigma Advisers LP raised its stake in Lyell Immunopharma by 143.8% during the 4th quarter. Two Sigma Advisers LP now owns 306,400 shares of the company's stock worth $196,000 after buying an additional 180,700 shares during the period. Millennium Management LLC boosted its holdings in Lyell Immunopharma by 34.8% in the fourth quarter. Millennium Management LLC now owns 957,507 shares of the company's stock worth $613,000 after acquiring an additional 247,440 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Lyell Immunopharma by 13.4% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 308,551 shares of the company's stock valued at $197,000 after acquiring an additional 36,555 shares during the period. Institutional investors and hedge funds own 66.05% of the company's stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a "neutral" rating and set a $1.00 price objective on shares of Lyell Immunopharma in a research report on Thursday, March 13th.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.